PHASE-XS is a database developed by Coherent Market Insights, a market intelligence and consulting company. This database provides clinical information about phase 3 and phase 4 products for biologics and biosimilars. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included in the PHASE-XS.
Benefits of PHASE-XS:
Identify the potential competitors in the future
Identify target products for biosimilars through patent expiry of biologics
Identify if there are any studies for the extension of indications of already approved products
Identify the white spaces
Identify the products with significant revenue opportunity
Identify an ideal trial design with a competitive edge
Actionable market forecast
Identify the addressable patient pool
In the past few years, biopharmaceutical products are preferred over conventional pharmaceutical products for the treatment of various diseases, as it reacts highly specific against a target, and has less side effects and low toxicity. Lack of oral absorption was one of the major drawbacks of biologics, for which new delivery systems have been developed.
Companies engaged in the development of biosimilars and biologics will find this database very useful. Many biopharmaceutical companies are focusing on developing biosimilars due to increasing incidence of chronic diseases in the U.S., patent expiry of branded drugs, and the increasing support from regulatory agencies such as the U.S. FDA. The U.S. FDA has made approval process of biopharmaceutical products such as biosimilars easily accessible. In November 2018, UDENYCA, a biosimilar to Neulasta (pegfilgrastim) was approved by the FDA for subcutaneous use and in October 2018, a biosimilar to Adalimumab, Hyrimoz received approval from the FDA.
Know more about the exclusive biologics and biosimilars by clicking the link below,
Therefore, to know more about biosimilar opportunity and the products that are under clinical trial, you can get access to PHASE-XS database through subscription service. Moreover, the data will be provided to the client in an excel sheet for better understanding. More information on PHASE-XS can be obtained through the link provided below.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Address:1001 4th Ave, #3200
Country: United States